Innovative contracting in Europe – a Trojan horse?Overview With pricing of drugs at the centre of political and social debate, the market access and pricing Share XInnovative contracting in Europe – a Trojan horse?https://pharmaphorum.com/market-access-2/innovative-contracting-in-europe-a-trojan-horse/
How pharma marketing can stay ahead of the evolving customer journeyOverview Join our live webinar taking place on Tuesday 23rd July at 16:00 BST / 11:00 EST / Share XHow pharma marketing can stay ahead of the evolving customer journeyhttps://pharmaphorum.com/digital/how-pharma-marketing-can-stay-ahead-of-the-evolving-customer-journey/
Launch excellence in a disrupted world – challenges & opportunitiesOverview The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care Share XLaunch excellence in a disrupted world – challenges & opportunitieshttps://pharmaphorum.com/market-access-2/launch-excellence-in-a-disrupted-world-challenges-opportunities/
Orphan medicines launch excellence: sustaining launch successOverview Launching orphan medicines excellently will become even more important over the next five years as more patients Share XOrphan medicines launch excellence: sustaining launch successhttps://pharmaphorum.com/market-access-2/orphan-medicines-launch-excellence-sustaining-launch-success/
Navigating new frontiers: Ways to find space in the future RA marketOverview Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 Share XNavigating new frontiers: Ways to find space in the future RA markethttps://pharmaphorum.com/r-d/navigating-new-frontiers-ways-to-find-space-in-the-future-ra-market/
The 2nd Life Sciences Sector Deal and the NHS 10 Year PlanOverview Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK Share XThe 2nd Life Sciences Sector Deal and the NHS 10 Year Planhttps://pharmaphorum.com/market-access-2/the-2nd-life-sciences-sector-deal-and-the-nhs-10-year-plan/
Cancer, genomics and personalised medicine: Modelling oncology’s futureOverview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in Share XCancer, genomics and personalised medicine: Modelling oncology’s futurehttps://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/
Metrics to meaning: demonstrating the value of medical communicationsOverview Medical affairs and publications teams are under increasing pressure to demonstrate effectively the success of the medical Share XMetrics to meaning: demonstrating the value of medical communicationshttps://pharmaphorum.com/sales-marketing/metrics-to-meaning-demonstrating-the-value-of-medical-communications/
Can simulated datasets unlock the potential of patient data?Overview Patient level data offers the promise of insights which can craft new and better pathways, enable development Share XCan simulated datasets unlock the potential of patient data?https://pharmaphorum.com/debates-insight-patients/can-simulated-datasets-unlock-the-potential-of-patient-data/
